• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Astagraf XL (tacrolimus extended-release capsules)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

February 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.14 Use with CYP3A4 Inhibitors and Inducers
5.15 QT Prolongation …added section
5.18 Gastrointestinal Perforation …added section

6 ADVERSE REACTIONS

  • Added bullet point…Gastrointestinal Perforation [see Warnings and Precautions (5.18)]

7 DRUG INTERACTIONS

  • Dose adjustments may be needed along with frequent monitoring of tacrolimus whole blood trough concentrations when ASTAGRAF XL is administered with CYP3A inhibitors or inducers. In addition, patients should be monitored for adverse reactions including changes in renal function and QT prolongation [see Warnings and Precautions (5.9) and (5.15)].